MacroGenics Stock (NASDAQ:MGNX)

MacroGenics, Inc. is a U.S.-based biopharmaceutical company specializing in the development and commercialization of antibody-derived treatments primarily aimed at combating cancer. The company's sole approved product is MARGENZA (margetuximab-cmkb). This drug acts as an antagonist to the human epidermal growth factor receptor 2 (HER2) and is prescribed in conjunction with chemotherapy for adult patients suffering from metastatic HER2-positive breast cancer who have previously undergone at least two different anti-HER2 treatment regimens. Beyond its commercialized medicine, MacroGenics boasts an extensive pipeline of investigational immuno-oncology therapies. These include: MGC018, an antibody-drug conjugate (ADC) engineered to target solid tumors that express B7-H3. Enoblituzumab, a monoclonal antibody also focused on B7-H3. MGD024, an experimental bispecific CD123 × CD3 DART molecule designed to mitigate cytokine-release syndrome in individuals with hematologic malignancies. Further assets in its development portfolio encompass: Lorigerlimab, a monoclonal antibody that modulates the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4. Tebotelimab, an investigational tetravalent DART molecule that interacts with PD-1 and lymphocyte-activation gene 3. Retifanlimab, a monoclonal antibody under investigation for metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer. IMGC936, an ADC targeting ADAM9, a cell surface protein frequently over-expressed across various solid tumor types. MacroGenics' research and development also extends to other therapeutic areas, featuring: MGD014 and MGD020, DART molecules constructed to bind to the envelope protein of human immunodeficiency virus-infected cells and CD3 on T cells. Teplizumab, a candidate drug for the management of type 1 diabetes. PRV-3279, a CD32B × CD79B DART molecule currently being explored for its potential in autoimmune conditions. To support its ambitious pipeline, MacroGenics has established strategic collaborations with several key partners, including Incyte Corporation, Zai Lab Limited, I-Mab Biopharma, and Janssen Biotech, Inc. The company was founded in 2000 and maintains its corporate headquarters in Rockville, Maryland.